+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review - 2020

  • PDF Icon

    Report

  • 142 Pages
  • September 2021
  • Region: Global
  • GlobalData
  • ID: 5458390
Description Jump to:
The publisher's"Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review - 2020" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in the year 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from the publisher's proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope


  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy


  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceutical & Healthcare, Global, Deals Summary
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2020
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2020
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2020
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2020
2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2020
3 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, 2020
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2020
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2020
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2020
3.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2020
3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2020
3.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2020
4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market
4.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2020
4.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2020
4.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2020
4.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2020
4.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2020
4.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2020
4.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2020
5 Pharmaceuticals & Healthcare, Deal Summary, By Geography
5.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2020
5.2 Pharmaceuticals & Healthcare, European Region Deals, 2020
5.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2020
5.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2020
6 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
6.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2020
6.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2020
7 Further Information
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclosure information
7.5 Disclaimer
List of Tables
Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2020-Q4 2020
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2020
Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2020
Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2020
Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2020
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 12 Pharmaceuticals & Healthcare, Global, Top IPOs, 2020
Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2020
Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2020
Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2020
Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2020
Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2016 - 2020
Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2020
Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2020
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2020
Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2020
Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2020
Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2020
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2020
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2020
Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2016 - Q4 2020
Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2020
Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2020
Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2020
Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2020
Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2020
Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2020
Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2020
Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2020
Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2020
Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2020
Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 - 2020
List of Figures
Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2016- 2020
Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2020-Q4 2020
Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2020
Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2020
Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2020
Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2020
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2020
Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2020
Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2020
Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2020
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2020
Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2020
Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2020
Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2020
Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2020
Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2020
Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2020
Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2020
Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2020
Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2020
Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2020
Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2020, 2016 - 2020
Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2016 - 2020
Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2020-Q4 2020
Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020
Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2016 - 2020
Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2020-Q4 2020

Related Topics

Related Reports

Artificial Intelligence (AI) in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, Natural Language Processing), Application (Medical Imaging & Diagnostics, Patient Data & Risk Analysis), End User & Region - Forecast to 2029 - Product Image

Artificial Intelligence (AI) in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, Natural Language Processing), Application (Medical Imaging & Diagnostics, Patient Data & Risk Analysis), End User & Region - Forecast to 2029

  • Report
  • 360 Pages
  • Global
From
Healthcare BPO - Global Strategic Business Report - Product Image

Healthcare BPO - Global Strategic Business Report

  • Report
  • 397 Pages
  • Global
From
Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029 - Product Image

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029

  • Report
  • 412 Pages
  • Global
From
Global Healthcare Industry Almanac 2024: Market Research, Statistics, Trends and Leading Companies - Product Image

Global Healthcare Industry Almanac 2024: Market Research, Statistics, Trends and Leading Companies

  • Book
  • 675 Pages
  • Global
From
Healthcare Environmental Services Global Market Report 2024 - Product Image

Healthcare Environmental Services Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.